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Abstract
Objective To develop a nomogram and validate its use for the intraoperative evaluation of nodal metastasis using shear-wave
elastography (SWE) elasticity values and nodal size
Methods We constructed a nomogram to predict metastasis using ex vivo SWE values and ultrasound features of 228 axillary
LNs from fifty-five patients. We validated its use in an independent cohort comprising 80 patients. In the validation cohort, a total
of 217 sentinel LNs were included.
Results We developed the nomogram using the nodal size and elasticity values of the development cohort to predict LN
metastasis; the area under the curve (AUC) was 0.856 (95% confidence interval (CI), 0.783–0.929). In the validation cohort,
15 (7%) LNs were metastatic, and 202 (93%) were non-metastatic. The mean stiffness (23.54 and 10.41 kPa, p = 0.005) and
elasticity ratio (3.24 and 1.49, p = 0.028) were significantly higher in the metastatic LNs than those in the non-metastatic LNs.
However, the mean size of the metastatic LNs was not significantly larger than that of the non-metastatic LNs (8.70 mm vs 7.20
mm, respectively; p = 0.123). The AUCwas 0.791 (95%CI, 0.668–0.915) in the validation cohort, and the calibration plots of the
nomogram showed good agreement.
Conclusions We developed a well-validated nomogram to predict LNmetastasis. This nomogram, mainly based on ex vivo SWE
values, can help evaluate nodal metastasis during surgery.
Key Points
• A nomogram was developed based on axillary LN size and ex vivo SWE values such as mean stiffness and elasticity ratio to
easily predict axillary LN metastasis during breast cancer surgery.
• The constructed nomogram presented high predictive performance of sentinel LN metastasis with an independent cohort.
• This nomogram can reduce unnecessary intraoperative frozen section which increases the surgical time and costs in breast
cancer patients.
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Introduction
Axillary lymph node (LN) metastasis is one of the important
prognostic factors in breast cancer [1, 2]. Sentinel LN biopsy
(SLNB) has become the standard method for axillary staging
in patients with clinically negative nodes [3]. Further, intraop-
erative pathologic assessment of sentinel LNs enables surgical
staging and aids in surgical decision-making regarding wheth-
er axillary LN dissection (ALND) should be performed during
surgery [4–7]. However, it requires skilled pathologists and
equipment, which increases the surgical time and costs.
Shear-wave elastography (SWE) can quantitatively calcu-
late the elasticity parameters of target lesions and provide
values, such asmean, minimum, andmaximum stiffness; stan-
dard deviation of elasticity; and elasticity ratio of breast le-
sions to the adjacent fat tissue. It is helpful in distinguishing
breast cancerous lesions because malignant tissues tend to
have increased stiffness compared with benign tissues
[8–12]. Also, SWE well predicted the histological upgrade
to invasive cancer in ductal carcinoma in situ confirmed at
biopsy and response to neoadjuvant chemotherapy in breast
cancer [13, 14]. Furthermore, several studies reported that
SWE could be applied to identify axillary LN metastasis as
well as breast malignancy [15–19]. In addition, we previously
reported that the nodal size and elasticity values, such as max-
imum stiffness, mean stiffness, and elasticity ratio of axillary
LNs to the adjacent fat tissues, were associated withmetastatic
axillary LNs [20]. Therefore, ex vivo SWE is thought to be a
feasible method to predict axillary LN metastasis.
Based on these results, we hypothesized that the nomogram
constructed using ultrasound features and elasticity values
measured via intraoperative ex vivo SWE can accurately pre-
dict nodal metastasis. Furthermore, the disadvantages of intra-
operative frozen section analysis may be compensated if the
nomogram precisely predicts sentinel LN metastasis, since
ex vivo SWE can be performed easily, and no additional
equipment is required, except for ultrasound. For this reason,
we developed and validated a nomogram to predict the senti-
nel LN metastasis using ultrasound features and ex vivo SWE
values in this study.
Materials and methods
Patients
In our previous prospective study, a total of 228 axillary LNs,
including sentinel LNs obtained from fifty-five patients who
underwent breast cancer surgery in Gangnam Severance
Hospital from May 2014 to April 2015, were investigated
[20]; these patients were utilized as the development cohort.
Another 80 patients diagnosed with breast cancer underwent
breast cancer surgery at the same hospital from August 2015
to March 2016 were prospectively enrolled. Patients with
stage IV cancer or those who received neoadjuvant chemo-
therapy were excluded. Unlike in the development cohort, 217
sentinel LNs obtained from these 80 patients examined using
intraoperative ex vivo SWE were included in the validation
cohort.
Our study was approved by the Institutional Review Board
of Gangnam Severance Hospital and conducted in accordance
with the Good Clinical Practice guidelines and the Declaration
of Helsinki principles.
SLNB
SLNB was performed using 99mTc-labeled tin colloid.
Intradermal injection of 0.4 mL 30 MBq (0.8 mCi) 99mTc
tin colloid diluted in normal saline solution was performed
at four peri-areolar sites. Sentinel LNs were determined by
employing a gamma detector (Gamma Detection System,
Neoprobe Corporation). The LNs showing a high radioactiv-
ity were dissected, after which the gamma detector was used
again to confirm the correct sentinel LNs. All radioactive LNs
with an account equal to or greater than 10% of the highest
radioactive LN were removed. When suspicious LNs not de-
tected by the gamma probe were found after SLNB, they were
removed and examined as non-sentinel LNs. If the result of
frozen pathology was positive for malignancy, ALND was
performed.
B-Mode ultrasound with ex vivo SWE
Excised LNs were delivered to the radiology part. Then,
B-mode ultrasound with ex vivo SWE was performed as men-
tioned in our previous study [20]. In summary, the nodal size
and elasticity values, such as mean stiffness and elasticity ratio
of the sentinel LNs to the adjacent fat tissues, were examined
during surgery via B-mode ultrasound and SWE using the
Aixplorer ultrasound system (Super Sonic Imagine) and
ShearWaveTM elastography mode [21, 22] with a 4–15-MHz
linear transducer. During the examination, the radiologists
need to handle the specimen carefully so as not to exert pressure
on the excised LNs by the ultrasound transducer and sufficient
contact jelly was used to avoid artificial stiffness. The longest
diameter of the LN which was hypoechoic compared with the
adjacent fat tissue was measured in B-mode ultrasound (Fig. 1).
After few seconds of immobilization to allow the SWE image
to stabilize, mean stiffness was measured by placing a fixed
2-mm circular region-of-interest (ROI) box (Q-BOXTM;
SuperSonic Imagine) on the stiffest region of the excised
LNs. The elasticity ratio was calculated automatically when
the first ROI was placed on the stiffest region of excised LNs,
and the other ROI was immediately placed on the adjacent fat
tissue (Fig. 1). Four radiologists with a clinical experience of
more than 2 years performed B-mode ultrasound with SWE,
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and one radiologist with more than 10 years of clinical experi-
ence reviewed the results, i.e., nodal size and elasticity values,
such as mean stiffness and elasticity ratio.
Pathologic evaluation of excised LNs
After the radiologic examination was finished, the pathologic
evaluation of sentinel LNs was performed. The excised senti-
nel LNs were cut into 2–3-mm sizes, and all slices were
assessed. The size of the metastatic lesions within the excised
nodes was reported in accordance with the staging system of
the American Joint Committee on Cancer as follows: > 2 mm,
macro-metastasis; 0.2–2.0 mm, micro-metastasis; and < 0.2
mm, isolated tumor cells [23]. In this study, sentinel LN me-
tastasis was defined as macro-metastasis.
Development of the nomogram and statistical
analysis
A nomogram was established on the basis of the results of the
multivariate analysis in the development cohort. Thereafter,
200 bootstrap samples were used for internal validation of
the development cohort, and external validation was per-
formed with an independent cohort. The performance of the
constructed nomograms was quantified with respect to dis-
crimination and calibration [24]. The discriminative power
of whether the constructed nomogram can correctly predict
Fig. 1 B-Mode ultrasound and shear-wave elastography (SWE). a B-
Mode ultrasound showed 0.73-cm–sized excised sentinel lymph node
with adjacent fat tissue. b The mean stiffness was measured by placing
the 2-mm–sized region-of-interest (ROI) on the stiffest part of the excised
sentinel lymph node (circle). The stiffness of the adjacent fat tissue was
measured by placing another ROI on the surrounding fat tissue (dotted
circle). Then, the elasticity ratio was calculated automatically. a–d B-
Mode ultrasound and shear-wave elastography (SWE) images of patients
with lymph node metastasis. e, f B-Mode ultrasound and shear-wave
elastography (SWE) images of patient without lymph node metastasis
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the probability of LN metastasis was quantified using the area
under the receiver operating characteristic curve. Calibration
was performed to identify the agreement between the ob-
served outcomes and predicted probabilities of metastasis
among the excised LNs. To verify the suitability of the con-
structed nomograms, the Hosmer-Lemeshow goodness-of-fit
test was performed [25, 26]. The software used to perform
these analyses was the SAS program (ver 9.2, SAS Institute
Inc.) or the R Statistical Package (ver 3.3.3, Institute for
Statistics and Mathematics).
The characteristics of the patients were analyzed using the
chi-square test and independent two-sample t test. The mean
elasticity values were compared between the non-metastatic
andmetastatic sentinel LNs using the independent two-sample
t test. Analysis was performed using the SPSS software ver 23
(SPSS).
Results
Nomogram construction using the development
cohort and internal validation
We previously reported the characteristics and elasticity
values of the harvested axillary LNs measured using
B-mode ultrasound and intraoperative ex vivo SWE in the
development cohort [20]. Briefly, the nodal size and elasticity
values, such as mean stiffness and elasticity ratio, were asso-
ciated with axillary LN metastasis in the multivariable analy-
sis. The nomogram was constructed on the basis of significant
factors from the multivariable analysis in the development
cohort to predict the probability of axillary LN metastasis
(Fig. 2a). From binary logistic regression model for multivar-
iable analysis, we obtained intercept and regression coefficient
of each significant factor. The probability of axillary LN me-
tastasis was calculated as follows: 1/(1 + exp(−A)),
where A = − 4.9898 + 0.1498 × (nodal size) + 0.0345 × (mean
stiffness) + 0.5321 × (ratio)
In the nomogram, the estimated probability of LN metas-
tasis could be obtained by summing the scores of each vari-
able and locating such on the total score scale. For instance, a
patient with a 16-mm nodal size (11 points), 70-kPa mean
stiffness (13 points), and 5 ratio (14 points) would score 38
points, which can be converted into 92.29% probability of LN
metastasis (Fig. 2b).
The area under the curve (AUC) was 0.856 (95% confi-
dence interval (CI), 0.783–0.929) in the development cohort
(Fig. 3a). The p value obtained using the Hosmer-Lemeshow
goodness-of-fit test was 0.354, indicating a good fit of the
model. When internal validation was performed using the
200 bootstrap samples, the mean absolute error was as low
as 0.029. Moreover, the calibration plots of the nomogram
showed good agreement between the observed and predicted
outcomes (Fig. 3b).
Validation cohort
In the validation cohort, 10 of the 80 patients had sentinel LN
metastases, all of which were in the N1 stage. Tumor size of
the patients with sentinel LNmetastasis was larger than that of
the patients without sentinel LN metastasis (2.35 cm vs 1.61
cm, p = 0.045). The other clinicopathologic factors were no
significantly different between the patients with and without
sentinel LN metastasis (Table 1). The median age of all pa-
tients was 55 (range, 22–76) years. The findings for estrogen
receptor (ER) and human epidermal growth factor receptor 2
(HER2) were positive in 67 (83.8%) and 15 (18.8%) patients,
respectively. T1 stage and grade 2 were the most common
classifications in 52 (65.0%) and 43 (53.8%) patients, respec-
tively. The number of elderly patients and patients with
HER2-negative findings and low N stage was higher in the
validation cohort than in the development cohort (Table 2).
Fig. 2 Constructed nomogram. a Constructed nomogram based on the predictive factors of axillary LN metastasis, such as nodal size, mean stiffness,
and elasticity ratio. b Example of constructed nomogram. LN, lymph node
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Of the 217 sentinel LNs, 15 (6.9%) were metastatic, and
202 (93.1%) were non-metastatic, including seven (3.2%)
micro-metastatic LNs. The metastatic LNs tended to be larger
than non-metastatic LNs, but it was not significant (8.70 mm
vs 7.20 mm, p = 0.123) (Table 3). The mean stiffness of the
metastatic sentinel LNs was significantly greater than that of
the non-metastatic sentinel LNs (23.54 vs 10.41 kPa, p =
0.005) (Fig. 4). Furthermore, the elasticity ratio of the meta-
static sentinel LNs was significantly higher than that of the
non-metastatic sentinel LNs (3.24 vs 1.49, p = 0.028).
Meanwhile, there was no difference in nodal size and elastic-
ity values according to histological types of breast cancer
(Table 4).
External validation of the nomogram
The nomogramwas validated with the independent set includ-
ing only 217 sentinel LNs. The discriminative power was
good, with an AUC of 0.791 (95% CI, 0.668–0.915) (Fig.
3c). The calibration plots of the nomogram showed good
agreement between the observed and predicted outcomes
(Fig. 3d).
Discussion
In this study, we generated a nomogram to predict metastatic
LNs based on nodal size and elasticity values such as mean
stiffness and elasticity ratio of harvested LNs on B-mode ul-
trasound with ex vivo SWE using data from our previous
study. Thereafter, we tested the predictive ability of the nomo-
gram in an independent set consisting of sentinel LNs. The
performance of constructed nomogram to predict sentinel LNs
metastasis was high in terms of good discrimination and
calibration.
Cancer researchers, clinicians, and the public are becoming
increasingly interested in statistical models designed to predict
the occurrence or the outcome of cancer, along with the effi-
cacy of treatments [25–27]. Among several predictionmodels,
nomograms have been shown to provide personalized reason-
able risk estimates that facilitate management-related deci-
sions [27]. Indeed, our nomogram can be used to calculate
the probability of each axillary LN metastasis easily and rap-
idly. When the total point calculated using the nodal size,
mean stiffness, and elasticity ratio is over 35 points, the prob-
ability of LNmetastasis exceeds 90%. If the total point is over
48 points, the probability of LN metastasis exceeds 99%.
Fig. 3 ROC curve of the
nomogram and the calibration
plot. a ROC curve of the
nomogram; b the calibration plot
in the development cohort with
internal validation; c ROC curve
of the nomogram; d the
calibration plot in the validation
cohort with external validation.
ROC, receiver operating
characteristic
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Table 1 Clinicopathologic
characteristics of the validation
cohort according to LNmetastasis
Variables Patients with non-malignant
sentinel LN (N = 70)
Patients with malignant
sentinel LN (N = 10)
All patients
(N = 80)
p value
Median age (years) 55.5 (35–76) 54 (22–75) 55 (22–76) 0.716
Tumor size (cm) 1.61 ± 1.07 2.35 ± 1.14 1.68 ± 1.06 0.045
T stage 0.520†
T1mi 2 (2.9%) 0 2 (2.5%)
T1 47 (67.1%) 5 (50.0%) 52 (65.0%)
T2 20 (28.6%) 5 (50.0%) 25 (31.3%)
T3 1 (1.4%) 0 1 (1.2%)
HG 0.312†
Grade I 18 (25.7%) 1 (10.0%) 19 (23.8%)
Grade II 38 (54.3%) 5 (50.0%) 43 (53.8%)
Grade III 14 (20.0%) 4 (40.0%) 18 (22.5%)
ER 0.662†
Positive 59 (84.3%) 8 (80.0%) 67 (83.8%)
Negative 11 (15.7%) 2 (20.0%) 13 (16.2%)
PR 0.715†
Positive 48 (68.6%) 8 (80.0%) 56 (70.0%)
Negative 22 (31.4%) 2 (20.0%) 24 (30.0%)
HER2 0.086†
Positive 11 (15.7%) 4 (40%) 15 (18.8%)
Negative 59 (84.3%) 6 (60%) 65 (81.3%)
LN, lymph node; HG, histologic grade; ER, estrogen receptor; PR, progesterone receptor; HER2, human epider-
mal growth factor receptor 2
† Fisher’s exact test
Table 2 Comparison of the
clinicopathologic characteristics
between the development and
validation cohorts
Characteristics Development cohort (N = 55) Validation cohort (N = 80) p value
Median age, years (range) 49 (31–69) 55 (22–76) 0.009*
Tumor size, cm (range) 1.75 (0.10–3.60) 1.70 (0.1–6.20) 0.766
T stage 0.382†
Tis 2 (3.6%) 0
T1mi 2 (3.6%) 2 (2.5%)
T1 31 (56.4%) 52 (65.0%)
T2 20 (36.4%) 25 (31.3%)
T3 0 1 (1.3%)
N stage < 0.001†
0 28 (51.0%) 70 (87.5%)
N1 19 (34.5%) 10 (12.5%)
N2 6 (11.0%) 0
N3 2 (3.5%) 0
HGa 0.096
Grade I 7 (12.7%) 19 (23.8%)
Grade II 25 (45.5%) 43 (53.8%)
Grade III 20 (36.4%) 18 (22.5%)
ER 0.074
Positive 39 (70.9%) 67 (83.8%)
Negative 16 (29.1%) 13 (16.2%)
PR 0.157
Positive 32 (58.2%) 56 (70.0%)
Negative 23 (41.8%) 24 (30.0%)
HER2 0.012
Positive 21 (38.2%) 15 (18.8%)
Negative 34 (61.8%) 65 (81.3%)
HG, histologic grade; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor
receptor 2
*Mann-Whitney test
† Fisher’s exact test
aMissing data
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Indeed, the mean total point in the nomogram was significant-
ly different between the non-metastatic and metastatic sentinel
LNs (Supplementary Table 3). In the metastatic sentinel LNs,
the probability of LN metastasis was approximately 70%, as
the mean total point was 28 points; in the non-metastatic sen-
tinel LNs, the probability of LNmetastasis was less than 10%,
as the mean total point was 8 points.
The discriminative power of the nomogram was quantified
using the AUC exhibiting the accuracy of the test, with an
AUC of 0.5 being defined as non-informative; 0.5–0.7, fair;
0.7–0.9, good; and > 0.9, excellent. Our nomogram revealed
good discriminative power with the AUC of 0.856 in the de-
velopment cohort and 0.791 in the validation cohort. In addi-
tion, the calibration plot showed good agreement between the
observed and predicted probabilities in both the development
and validation cohorts. Therefore, our constructed nomogram
was suitable in predicting the probability of metastasis among
the harvested sentinel LNs.
In the validation cohort, the ultrasound and SWE charac-
teristics of sentinel LNs were not different between histologic
types of breast cancer in line with previous report [28]. The
mean stiffness and elasticity ratio of the metastatic sentinel
LNs were significantly higher than those of the non-
metastatic LNs. These findings are similar to those of the
development cohort in our previous study. The nodal size
tended to be larger in the metastatic LNs than in the non-
metastatic LNs, although the trend was not significant. It
was presumed that the proportion of the metastatic LNs was
higher in the development cohort than in the validation cohort
(Table 2). Further research with a larger number of axillary
LNs is needed to investigate the accurate relationship between
the nodal size and LN metastasis.
Recently, the American College of Surgeons Oncology
Group Z0011 prospective, randomized clinical trial changed
the standard approach to axillary surgery, showing that the
omission of ALND was possible in early breast cancer pa-
tients who underwent breast conserving surgery and adjuvant
systemic therapy even with 1–2 metastatic sentinel LNs [29,
30]. Several previous trials also reported consistent findings
with those of the Z0011 trial [2, 31]. Since these trials present-
ed that ALND could be omitted even in patients with positive
sentinel LNs, the need for intraoperative frozen section anal-
ysis of sentinel LNs is questionable. In fact, not only ALND
but also intraoperative frozen section analysis of sentinel LNs
in patients who underwent breast conservative surgery was
declined after the Z0011 trial was published [32, 33].
Table 3 Ultrasound features and
elasticity values measured using
intraoperative ex vivo shear-wave
elastography and total points in
the nomogram between the non-
metastatic and metastatic axillary
LNs
Total
(n = 217)
Non-metastatic
sentinel LNs
(n = 202)
Metastatic sentinel LNs
(n = 15)
p value
Nodal size (mm) 7.31 ± 3.63 7.20 ± 3.62 8.70 ± 3.60 0.123
Mean stiffness (kPa) 11.32 ± 7.2 10.41 ± 5.24 23.54 ± 15.28 0.005
Elasticity ratio 1.61 ± 1.12 1.49 ± 0.77 3.24 ± 2.76 0.028
Total points in nomogram 9.08 (95% CI,
7.54–10.62)
7.67 (95% CI,
6.69–8.64)
28.06 (95% CI, 11.29–44.83) < 0.001*
LN, lymph node
*Mann-Whitney test
Fig. 4 Ultrasound feature and elasticity values between non-metastatic andmetastatic lymph nodes. Box plot of the (a) nodal size, (b) mean stiffness, and
(c) elasticity ratio between the non-metastatic and metastatic lymph nodes
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Furthermore, Noordaa et al suggested that omitting intraoper-
ative pathologic assessment of LNs was a reasonable option in
patients with a low nodal burden, such as clinically node-
negative breast cancer, who were treated with upfront surgery
[34].
However, one of the major disadvantages of omitting
intraoperative frozen section analysis is secondary surgery
for ALND. To date, the exact rate of secondary surgery for
ALND after skipping intraoperative frozen section analysis
has not been well researched. Nevertheless, concerns of
secondary operation for ALND can be reduced if intraop-
erative pathologic examination was performed for sentinel
LNs in suspicion of metastasis, as identified by our
nomogram.
Our study has some limitations. First, the cutoff value of
nomogram to determine the intraoperative pathologic exami-
nation was not clarified in this analysis. Further prospective
studies are needed to verify this issue. Second, the rate of
metastatic LNs in the validation cohort was lower than that
in the development cohort. It was probably because only sen-
tinel LNs were included in the validation set. The number of
metastatic LNs was 15 in the validation cohort of our study;
nevertheless, these events were statistically sufficient to per-
form calibration and discrimination to warrant the use of our
nomogram. Finally, concerns about the reproducibility of
SWE still remained because interobserver or intraobserver
agreements for the elasticity values were not assessed in this
study. However, the other previous study showed reliable
intraobserver and interobserver reproducibilities of SWE
[35, 36]. In addition, the reproducibility of SWEwas expected
to be higher in our study because specialized radiologists ex-
amined the LNs by ex vivo SWE that was less likely to inter-
fere with surrounding tissue compared with in vivo SWE.
Hence, it might be expected to precisely perform intraopera-
tive ex vivo SWE of excised LNs within a short time.
In conclusion, our well-validated nomogram can be applied
to predict nodal metastasis during SLNB. The clinical appli-
cation of nomogram, which is mainly based on ex vivo SWE
values, may help in reducing unnecessary intraoperative fro-
zen section analysis as well as secondary operation rate in
breast cancer patients who underwent SLNB.
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